Nova Eye Medical Ltd (ASX: EYE) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Nova Eye Medical Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$48.42 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
284.83 million
Earnings per share
-0.037
Dividend per share
N/A
Year To Date Return
16.98%
Earnings Yield
N/A
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Nova Eye Medical Ltd (ASX: EYE)
Latest News
⏸️ Investing
3 exciting small cap healthcare shares to buy today
⏸️ Investing
Why these 4 ASX shares started the week higher
⏸️ Investing
Top stock picks for December
⏸️ Investing
3 companies positioned to win big in 2018
⏸️ Investing
5 shares you need to watch on Tuesday
⏸️ Investing
2 top healthcare companies I'm watching like a hawk
⏸️ Investing
Top stock picks for September
⏸️ Investing
Why these 4 ASX shares are ending the week deep in the red
⏸️ Investing
3 little known companies I'm watching like a hawk
⏸️ Investing
3 ASX shares at 52-week lows: Are they bargain buys?
⏸️ Investing
Why these 4 ASX shares are ending the week deep in the red
⏸️ Investing
Why the Ellex Medical Lasers Limited share price fell 14% today
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 21 Jul 2020 | $0.1350 | 100.00% | Special Cash | 29 Jul 2020 |
EYE ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Nova Eye Medical Ltd
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
EYE Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Jan 2026 | $0.17 | $0.00 | 0.00% | 865,926 | $0.18 | $0.19 | $0.17 |
| 12 Jan 2026 | $0.18 | $0.02 | 12.90% | 2,434,609 | $0.16 | $0.18 | $0.16 |
| 09 Jan 2026 | $0.16 | $0.01 | 6.67% | 110,541 | $0.16 | $0.16 | $0.15 |
| 08 Jan 2026 | $0.15 | $0.00 | 0.00% | 238,549 | $0.15 | $0.16 | $0.15 |
| 07 Jan 2026 | $0.15 | $0.01 | 6.90% | 105,300 | $0.15 | $0.15 | $0.15 |
| 06 Jan 2026 | $0.15 | $0.00 | 0.00% | 219,286 | $0.15 | $0.15 | $0.14 |
| 05 Jan 2026 | $0.14 | $0.00 | 0.00% | 148,713 | $0.14 | $0.15 | $0.14 |
| 02 Jan 2026 | $0.14 | $0.01 | 7.55% | 666,672 | $0.14 | $0.14 | $0.13 |
| 31 Dec 2025 | $0.13 | $0.00 | 0.00% | 344,129 | $0.14 | $0.14 | $0.13 |
| 30 Dec 2025 | $0.13 | $-0.01 | -7.41% | 31,478 | $0.14 | $0.14 | $0.13 |
| 29 Dec 2025 | $0.14 | $0.00 | 0.00% | 470,457 | $0.14 | $0.14 | $0.13 |
| 24 Dec 2025 | $0.14 | $0.00 | 0.00% | 22,678 | $0.14 | $0.14 | $0.14 |
| 23 Dec 2025 | $0.14 | $0.00 | 0.00% | 475,031 | $0.13 | $0.14 | $0.13 |
| 22 Dec 2025 | $0.13 | $0.00 | 0.00% | 80,483 | $0.13 | $0.14 | $0.13 |
| 19 Dec 2025 | $0.13 | $0.00 | 0.00% | 146,221 | $0.14 | $0.14 | $0.13 |
| 18 Dec 2025 | $0.13 | $0.00 | 0.00% | 161,420 | $0.13 | $0.14 | $0.13 |
| 17 Dec 2025 | $0.13 | $0.00 | 0.00% | 274,357 | $0.14 | $0.14 | $0.13 |
| 16 Dec 2025 | $0.14 | $-0.01 | -6.90% | 216,350 | $0.15 | $0.15 | $0.14 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 01 Sep 2025 | Thomas (Tom) Spurling | Buy | 78,273 | $11,740 |
Off-market trade.
|
| 04 Aug 2025 | Thomas (Tom) Spurling | Issued | 300,000 | $45,000 |
Conversion of securities.
|
| 26 Mar 2025 | Mike Southard | Issued | 41,666 | $4,999 |
Placement.
|
| 26 Mar 2025 | Daniel Webb | Issued | 416,666 | $49,999 |
Placement.
|
| 26 Mar 2025 | Victor Previn | Issued | 416,666 | $49,999 |
Placement.
|
| 26 Mar 2025 | Thomas (Tom) Spurling | Issued | 166,666 | $19,992 |
Placement.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Victor Previn | Executive DirectorExecutive Chairman | Jul 2001 |
Mr Previn is a professional engineer and one of the original founders of the Company. His career spans more than 40 years in both the ophthalmic laser industry and the wider ophthalmic device sector. Mr Previn was elected Chairman of the Board of Directors. He is also a member of the Risk Committee.
|
| Mr Thomas (Tom) Anthony Spurling | Managing Director | Aug 2020 |
Mr Spurling has 30 years of senior executive experience serving in a range of commercial and management roles in Australia and the United States.
|
| Mr Rahmon Coupe | Non-Executive Director | May 2013 |
Mr Coupe has 37 years of experience in the areas of corporate management, intellectual property management, contract negotiation, business development and engineering and has worked across a range of industries, including information technology, life sciences and public broadcasting. He is currently a member of the Risk Committee.
|
| Mr Mike Southard | Non-Executive Director | Dec 2019 |
Mr Southard spent 26 years with Alcon Laboratories of Fort Worth, Texas, as Vice President of the Global Surgical business. Prior to this, he was an Executive with Beecham Laboratories (now SmithKline Beecham), and Cooper-Vision, which was acquired by Alcon Laboratories. Mike is currently actively involved in ophthalmology, dermatology and orthopaedics through his consulting company based in Portland, Oregon, USA. He has experience in both the International and US markets.
|
| Mr Daniel Webb | Non-Executive Director | Nov 2022 |
Mr Webb is based in Toronto, Canada and has a career that has spanned over 40 years in the marketing, sale and distribution of medical devices. After spending 10 years in various positions in ophthalmic device sales, Dan commenced his career with the medical laser company Coherent. In 1990 Dan established Coherent-AMT, now known as Clarion Medical Technologies (Clarion) to import, market, sell and distribute a range of medical devices, focusing on ophthalmic, aesthetic and surgical devices, in Canada.
|
| Mr Simon Ramsey Alexander Gray | Company Secretary | Jun 2020 |
-
|
| Simon Ramsey Alexander Gray | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 52,624,920 | 18.48% |
| J P Morgan Nominees Australia Pty Limited | 10,446,115 | 3.67% |
| Sedico Pty Ltd <Victor Previn Family A/C> | 7,945,355 | 2.79% |
| Ruminator Pty Ltd | 5,694,759 | 2.00% |
| Canala Super Fund Pty Ltd <Giuseppe Canala Sf A/C> | 4,515,857 | 1.59% |
| Highlands Investments Holdings Pty Ltd | 3,600,113 | 1.26% |
| Sean Barrett Pty Ltd <Super Fund A/C> | 3,526,847 | 1.24% |
| Citicorp Nominees Pty Limited | 3,433,696 | 1.21% |
| Dinwoodie Investments Pty Ltd | 3,105,954 | 1.09% |
| Mr Campbell Dinwoodie Taylor & Miss Sarah Joan Curtis <Cambet Super Fund A/C> | 2,718,318 | 0.95% |
| Super Wide Pty Ltd <Super Wide Super Fund A/C> | 2,689,831 | 0.94% |
| Sedico Pty Ltd <Victor Previn Superfund A/C> | 2,258,373 | 0.79% |
| Mr Robert Min | 2,167,262 | 0.76% |
| Mrs Glenis Nita O'Donnell | 2,060,000 | 0.72% |
| Super Success Pty Ltd <Super Success Fam Super A/C> | 2,050,000 | 0.72% |
| BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> | 2,043,910 | 0.72% |
| Mr Maximilian Django Jacobson Rudd | 2,000,000 | 0.70% |
| Mr Robert Brydon Rudd | 1,950,000 | 0.68% |
| Sharesies Australia Nominee Pty Limited | 1,871,789 | 0.66% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 1,847,751 | 0.65% |
